177 related articles for article (PubMed ID: 28114907)
1. The temporal impact of aging on the burden of herpes zoster.
Varghese L; Standaert B; Olivieri A; Curran D
BMC Geriatr; 2017 Jan; 17(1):30. PubMed ID: 28114907
[TBL] [Abstract][Full Text] [Related]
2. Cost of shingles: population based burden of disease analysis of herpes zoster and postherpetic neuralgia.
Friesen KJ; Chateau D; Falk J; Alessi-Severini S; Bugden S
BMC Infect Dis; 2017 Jan; 17(1):69. PubMed ID: 28086817
[TBL] [Abstract][Full Text] [Related]
3. A systematic literature review of the epidemiology and burden of herpes zoster in selected locales in Asia Pacific.
Chen J; Abrahamson PE; Ke Y; Ong CR; Parikh R; Shantakumar S
Hum Vaccin Immunother; 2024 Dec; 20(1):2344983. PubMed ID: 38767209
[TBL] [Abstract][Full Text] [Related]
4. Costs of herpes zoster complications in older adults: A cohort study of US claims database.
Meyers JL; Candrilli SD; Rausch DA; Yan S; Patterson BJ; Levin MJ
Vaccine; 2019 Feb; 37(9):1235-1244. PubMed ID: 30685248
[TBL] [Abstract][Full Text] [Related]
5. Cost of herpes zoster and herpes zoster-related complications among immunocompromised individuals.
Meyers JL; Candrilli SD; Rausch DA; Yan S; Patterson BJ; Levin MJ
Vaccine; 2018 Oct; 36(45):6810-6818. PubMed ID: 30249425
[TBL] [Abstract][Full Text] [Related]
6. Analysis of real-world health care costs among immunocompetent patients aged 50 years or older with herpes zoster in the United States.
Meyers JL; Madhwani S; Rausch D; Candrilli SD; Krishnarajah G; Yan S
Hum Vaccin Immunother; 2017 Aug; 13(8):1861-1872. PubMed ID: 28605285
[TBL] [Abstract][Full Text] [Related]
7. Increasing trends of herpes zoster in Australia.
MacIntyre R; Stein A; Harrison C; Britt H; Mahimbo A; Cunningham A
PLoS One; 2015; 10(4):e0125025. PubMed ID: 25928713
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
Pellissier JM; Brisson M; Levin MJ
Vaccine; 2007 Nov; 25(49):8326-37. PubMed ID: 17980938
[TBL] [Abstract][Full Text] [Related]
9. Economic Burden of Herpes Zoster ("culebrilla") in Latin America.
Rampakakis E; Pollock C; Vujacich C; Toniolo Neto J; Ortiz Covarrubias A; Monsanto H; Johnson KD
Int J Infect Dis; 2017 May; 58():22-26. PubMed ID: 28267595
[TBL] [Abstract][Full Text] [Related]
10. Healthcare Resource Utilisation Associated with Herpes Zoster in a Prospective Cohort of Older Australian Adults.
Karki S; Newall AT; MacIntyre CR; Heywood AE; McIntyre P; Banks E; Liu B
PLoS One; 2016; 11(8):e0160446. PubMed ID: 27483007
[TBL] [Abstract][Full Text] [Related]
11. Estimated Human and Economic Burden of Four Major Adult Vaccine-Preventable Diseases in the United States, 2013.
McLaughlin JM; McGinnis JJ; Tan L; Mercatante A; Fortuna J
J Prim Prev; 2015 Aug; 36(4):259-73. PubMed ID: 26032932
[TBL] [Abstract][Full Text] [Related]
12. The humanistic, economic and societal burden of herpes zoster in Europe: a critical review.
Gater A; Uhart M; McCool R; Préaud E
BMC Public Health; 2015 Feb; 15():193. PubMed ID: 25880058
[TBL] [Abstract][Full Text] [Related]
13. Herpes zoster and postherpetic neuralgia in Catalonia (Spain).
Salleras L; Salleras M; Salvador P; Soldevila N; Prat A; Garrido P; Domínguez A
Hum Vaccin Immunother; 2015; 11(1):178-84. PubMed ID: 25483532
[TBL] [Abstract][Full Text] [Related]
14. Annual incidence rates of herpes zoster among an immunocompetent population in the United States.
Johnson BH; Palmer L; Gatwood J; Lenhart G; Kawai K; Acosta CJ
BMC Infect Dis; 2015 Nov; 15():502. PubMed ID: 26546419
[TBL] [Abstract][Full Text] [Related]
15. Cost-benefit analysis of universal varicella vaccination in the U.S. taking into account the closely related herpes-zoster epidemiology.
Goldman GS
Vaccine; 2005 May; 23(25):3349-55. PubMed ID: 15837242
[TBL] [Abstract][Full Text] [Related]
16. Herpes zoster burden in patients with asthma: real-world incidence, healthcare resource utilisation and cost.
Singer D; Thompson-Leduc P; Ma S; Gupta D; Cheng WY; Muthukumar A; Devine F; Sundar M; Bogart M; Hagopian E; Poston S; Duh MS; Oppenheimer JJ
BMJ Open Respir Res; 2024 Jun; 11(1):. PubMed ID: 38862238
[TBL] [Abstract][Full Text] [Related]
17. Disease Burden Due to Herpes Zoster among Population Aged ≥50 Years Old in China: A Community Based Retrospective Survey.
Li Y; An Z; Yin D; Liu Y; Huang Z; Xu J; Ma Y; Tu Q; Li Q; Wang H
PLoS One; 2016; 11(4):e0152660. PubMed ID: 27055179
[TBL] [Abstract][Full Text] [Related]
18. Healthcare resource utilization and costs associated with herpes zoster in the US.
Johnson BH; Palmer L; Gatwood J; Lenhart G; Kawai K; Acosta CJ
J Med Econ; 2016 Oct; 19(10):928-35. PubMed ID: 27149530
[TBL] [Abstract][Full Text] [Related]
19. Projections of zoster incidence in Australia based on demographic and transmission models of varicella-zoster virus infection.
Costantino V; Gidding HF; Wood JG
Vaccine; 2017 Dec; 35(48 Pt B):6737-6742. PubMed ID: 29050801
[TBL] [Abstract][Full Text] [Related]
20. Acute/subacute herpes zoster: healthcare resource utilisation and costs in a group of US health plans.
Insinga RP; Itzler RF; Pellissier JM
Pharmacoeconomics; 2007; 25(2):155-69. PubMed ID: 17249857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
